Indicated for the treatment of signs and symptoms of Benign Prostatic Hyperplasia (BPH) in men with an enlarged prostate, for up to 26 weeks.

Finasteride: A specific inhibitor of steroid Type II 5α‑reductase. This enzyme converts testosterone into dihydrotestosterone (DHT). By lowering DHT levels, Finasteride reduces prostate growth and leads to shrinkage of the enlarged prostate gland.
Tadalafil: A selective inhibitor of phosphodiesterase type‑5 (PDE5). It relaxes smooth muscles of the prostate and surrounding urethra, improving urine flow and reducing BPH symptoms.

Adults: One capsule orally once daily at the same time, preferably on an empty stomach, for up to 26 weeks. Not recommended beyond 26 weeks.
Pediatric Use: Not established for patients under 18 years.
Geriatric Use: No significant differences in safety or efficacy observed in patients ≥65 years.
Hepatic Impairment: Use with caution in moderate impairment; not recommended in severe impairment.
Renal Impairment: Not recommended if creatinine clearance <50 mL/min or in patients undergoing hemodialysis.

Nitrates: Contraindicated with organic nitrates due to risk of severe hypotension.
Alpha‑Blockers: Caution advised. Discontinue alpha‑blockers at least one day before starting Urotide for BPH treatment.